{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:24:20Z","timestamp":1784175860300,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pancreatic tumors are highly lethal and a leading cause of cancer mortality. While systemic chemotherapy is the mainstay for advanced disease, its efficacy remains limited. KRAS mutations occur in approximately 88% of pancreatic ductal adenocarcinoma (PDAC), of which KRAS G12D comprises up to 39.5%. Despite the promise of KRAS G12D inhibitors, drug resistance persists. Combining KRAS and EGFR inhibitors has shown clinical efficacy in select solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the safety and efficacy of HRS-4642 (KRAS G12D inhibitor) plus nimotuzumab (EGFR inhibitor) in patients harboring the KRAS G12D mutation, recurrent\/metastatic PDAC refractory to standard systemic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This is an open-label, single-center, exploratory clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study will enroll patients with histologically or cytologically confirmed recurrent or metastatic PDAC harboring the KRAS G12D mutation, who have documented disease progression or intolerance to first-line systemic therapy. In Phase Ib, the safety profile of the investigational agent HRS-4642 will be assessed starting at an initial dose of 1,200\u00a0mg administered every 2\u00a0weeks (Q2W). Dose reductions to 1,000\u00a0mg Q2W or 800\u00a0mg Q2W will be implemented for dose-limiting toxicities. The recommended Phase II dose (RP2D) of HRS-4642 in combination with nimotuzumab (400\u00a0mg weekly, QW) will be determined based on safety and preliminary efficacy evaluation. Phase II will employ Simon\u2019s two-stage minimax design, with planned enrollment of approximately 20 participants. The primary endpoints for Phase Ib are safety profile characterization and RP2D determination; secondary endpoints include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DoR). For Phase II, the primary endpoint is ORR, with secondary endpoints comprising PFS, OS, DCR, safety, and DoR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This exploratory clinical trial may yield critical safety\/efficacy data supporting novel combination therapy for advanced PDAC. Its findings could advance the application paradigm of dual-target inhibition in pancreatic cancer therapeutics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>This study was registered on <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> with NCT06773130.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics<\/jats:title><jats:p>This study protocol has been approved by the Ethics Committee of West China Hospital [2024 (2239)].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1562481","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:26:50Z","timestamp":1751606810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib\/II trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Qingqing","family":"Leng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"B1","article-title":"ASCO GI oral 604","year":"2024"},{"key":"B2","first-page":"3007","volume-title":"ASCO oral abstract","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.3390\/curroncol31060250","article-title":"Radio chemotherapy in pancreatic cancer","volume":"31","author":"Domaga\u0142a-Haduch","year":"2024","journal-title":"Curr. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stem.2023.11.011","article-title":"A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS","volume":"31","author":"Duan","year":"2024","journal-title":"Cell. Stem Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","article-title":"Feedback activation of EGFR\/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer","volume":"42","author":"Feng","year":"2023","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","first-page":"LBA8511","DOI":"10.1200\/jco.2024.42.17_suppl.lba8511","article-title":"KROCUS: a phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC","volume":"42","author":"Gregorc","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.ctrv.2021.102309","article-title":"KRAS Inhibitors-yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond","volume":"101","author":"Nagasaka","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B12","article-title":"NCCN guidelines version 2.2024. Pancreatic adenocarcinoma","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-Mutated non-small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MPA.0000000000000389","article-title":"Targeting epidermal growth factor receptor-related signaling pathways in pancreatic cancer","volume":"44","author":"Philip","year":"2015","journal-title":"Pancreas"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/a:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3322\/caac.21190","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell."},{"key":"B24","doi-asserted-by":"crossref","first-page":"S1273","DOI":"10.1016\/j.annonc.2023.10.025","article-title":"LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1562481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:26:51Z","timestamp":1751606811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1562481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":23,"alternative-id":["10.3389\/fphar.2025.1562481"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1562481","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"article-number":"1562481"}}